Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
On July 14, 2021, the Society for Information Display (SID) announced a significant increase in the Impact Factor (IF) of its flagship publication, the Journal of the Society for Information Display (JSID), now at 2.140. This improvement reflects the journal's enhanced standing in the field, recognized through data compiled from Clarivate's Web of Science. This data supports scholarly evaluation and promotes quality academic publishing. JSID editor Jiun-Haw Lee emphasized the journal's prestige, highlighting contributions from renowned figures in the display industry.
On July 14, 2021, Clarivate Plc (NYSE:CLVT) announced the integration of its CompuMark™ trademark research and protection solutions into IPfolio™ and FoundationIP™. This move aims to streamline intellectual property (IP) management, enhancing data quality and reducing manual entry efforts. With global coverage of over 180 trademark authorities, the integration allows corporate IP departments and law firms to manage portfolios more efficiently. The strategy is designed to empower customers, fostering informed decision-making and operational excellence in IP management.
Clarivate Plc (NYSE:CLVT) released a report highlighting innovation in electric vehicles (EVs), identifying key challenges such as vehicle charging time and battery capacity as critical barriers to market potential. The report shows a surge in academic research on EVs, with 74% of papers published from 2011-2020. Despite advancements, consumer concerns about inadequate charging infrastructure persist. The report also discusses geographic trends in R&D, revealing major EV innovation hotspots in Japan, China, South Korea, Germany, and the US, along with increasing litigation activity in Europe and Asia.
On July 7, 2021, Clarivate Plc (NYSE: CLVT) announced significant upgrades to its Web of Science platform, enhancing the research experience for users. These improvements include new visualization tools like Author Impact Beamplots, enriched cited references, and detailed funding data for published works. The platform now supports advanced search workflows and allows easier sharing of search queries. These enhancements aim to simplify access to world-class research data and improve the overall functionality, promoting better collaboration among researchers.
Clarivate Plc (NYSE:CLVT) announced significant changes to its executive leadership team, welcoming Steen Lomholt-Thomsen as Chief Revenue Officer and Jaspal Chahal as Chief Legal Officer. Gordon Samson is promoted to President of the IP Group. The changes aim to strengthen customer engagement and accelerate integration of recent acquisitions, including Decision Resources Group and CPA Global. CEO Jerre Stead emphasized the importance of these appointments for driving innovation and growth while thanking Steve Hartman and Jeff Roy for their contributions to the company.
Clarivate Plc (NYSE: CLVT) will report its financial results for the second quarter 2021 on July 29, 2021, before market opening. The results, along with detailed financial information, will be available on the investor relations website. A conference call and webcast will take place on the same day at 8:00 AM ET to discuss these results. Interested parties can participate through a live audio broadcast or access a replay afterwards. For more details, visit this link.
Clarivate (NYSE:CLVT) has launched its 2021 update of the Journal Citation Reports (JCR), providing enhanced tools for researchers and publishers. The release features data from over 20,000 journals in multiple research categories, a new Journal Citation Indicator for improved citation impact analysis, and an upgraded user interface for easier navigation. Additionally, 8,771 new journals were added, greatly expanding the available content.
Clarivate Plc (NYSE: CLVT) released a Global Research Report focusing on how nations and institutions respond to challenges in science and technology. The study analyzes research portfolios from G7 and BRICK nations over 1981-2018, revealing that research diversity enhances resilience, particularly during the COVID-19 pandemic. With 67,756 COVID-19 related papers indexed in 2020-21, the report illustrates how a diverse research base yields innovative solutions. The Gini coefficient was utilized for comprehensive analysis, highlighting the potential of research diversity as a strategic tool for investment planning.
Clarivate Plc (NYSE: CLVT) announced the pricing of a $1.0 billion private offering of 3.875% senior secured notes due 2028 and $1.0 billion of 4.875% senior notes due 2029. The offering's proceeds will finance the acquisition of ProQuest, set to finalize by November 8, 2021, and cover associated fees. The notes will not be guaranteed before the acquisition but will be secured by escrow accounts. The offering is intended for qualified institutional buyers, with interests payable semi-annually starting December 30, 2021.
Clarivate Plc (NYSE: CLVT) announced a private offering of up to $1.0 billion in senior secured notes due 2028 and $1.0 billion in senior unsecured notes due 2029. The offering, subject to market conditions, aims to finance the purchase price for the pending acquisition of ProQuest, announced on May 17, 2021. The proceeds will be held in escrow until acquisition conditions are met, with redemption provisions if conditions are not satisfied by November 8, 2021. The notes will be secured prior to acquisition completion and will be guaranteed by subsidiaries post-acquisition.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
